Somerville, NJ, United States of America

Nicholas J Hrib

This inventor holds 42 USPTO granted patents, plus 1 CIPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Hoechst Roussel Pharmaceuticals, Hoechst Marion Roussel, Aventis Pharmaceuticals Inc.. Active years: 1988-2009.


% Patents Active = 90.5


Average Co-Inventor Count = 1.8

ph-index = 6

Forward Citations = 207(Granted Patents)


Location History:

  • Somerville, NJ (US) (1988 - 2001)
  • Hillsborough, NJ (US) (2006 - 2009)

Company Filing History:


Years Active: 1988-2009

Loading Chart...
Loading Chart...
Areas of Expertise:
Piperazine Derivatives
Oxelabdanes
Forskolin Synthesis
Thiazolidinones
Antipsychotic Agents
Alkoxycarbonylalkylphospholipids
Indole Derivatives
Heteroarenylpiperazines
Carboxamides
Anxiety Treatment
Chemical Synthesis
Pharmaceutical Compounds
42 patents (USPTO):Explore Patents

Title: The Innovative Journey of Nicholas J Hrib

Introduction:

Nicholas J Hrib, a talented inventor hailing from Somerville, NJ, has made significant contributions to the field of technology with his creative and groundbreaking ideas.

Latest Patents:

Nicholas J Hrib holds several patents in various technological domains, showcasing his versatility and ingenuity in inventing new solutions to complex problems.

Career Highlights:

Throughout his illustrious career, Nicholas J Hrib has consistently pushed the boundaries of innovation, earning recognition for his cutting-edge inventions that have had a profound impact on the industry.

Collaborations:

Nicholas J Hrib has collaborated with leading tech companies and research institutions, leveraging his expertise to drive collaborative projects that have resulted in groundbreaking innovations.

Conclusion:

Nicholas J Hrib's passion for innovation and his relentless pursuit of excellence have established him as a prominent figure in the world of inventors, inspiring the next generation of innovators to dream big and think outside the box.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…